ClinicalTrials.gg
CompletedNCT04502030Updated Nov 2, 2026Results posted

Double-blind, Randomized, Placebo-controlled, Prospective Phase III Study Evaluating Efficacy and Safety of Panzyga in Primary Infection Prophylaxis in Patients With Chronic Lymphocytic Leukemia ("PRO-SID" Study)

A Phase 3 interventional study of Panzyga and Placebo in Chronic Lymphocytic Leukemia and Hypogammaglobulinemia, sponsored by Octapharma. Completed at 84 sites in 12 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-02.

Sponsored by Octapharma · Phase 3, Interventional, and Prevention

Updated Nov 2, 2026Results postedStudy documents posted+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
247
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,501 studies in Leukemia, Lymphocytic, Chronic, B-Cell with a site in United States — 138 open to participants now, 252 under way, 34 of them phase 3. Leukemia, Lymphocytic, Chronic, B-Cell · United States.

Enrollment
103rd of 1,298
247 · median 36
Started
2020
with 49 others
Phase 3
114 of 1,501
17 open now
Registered
1,294th of 1,501
by date

Among the 1,501 studies in Leukemia, Lymphocytic, Chronic, B-Cell with a site in United States, this one is the 103rd largest by enrollment of the 1,298 interventional ones that give a count, is one of 50 that started in 2020, is one of 114 in phase 3, and was the 1,294th registered.

Leukemia, Lymphocytic, Chronic, B-Cell

2,036 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 236 are open to participants now.

Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →

Open to participants now

138 of the 1,501 studies in Leukemia, Lymphocytic, Chronic, B-Cell with a site in United States are open now. Recruiting first, the newest first:

133 more — sign in →

All 138 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 187 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 150 (80%) set no upper age limit and 15 (8%) stop at 75 or younger; 17 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,501 studies in Leukemia, Lymphocytic, Chronic, B-Cell with a site in United States, or all of them as a file.
02

Study summary

Study Evaluating Efficacy and Safety of Panzyga in Primary Infection Prophylaxis in Patients with Chronic Lymphocytic Leukemia

03

Conditions studied

  • Chronic Lymphocytic Leukemia
  • Hypogammaglobulinemia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Treatment-naïve or CLL patients undergoing CLL antineoplastic treatment. Diagnosis of B-cell CLL established according to International Workshop on Chronic Lymphocytic Leukemia (iwCLL) criteria and documented within medical records.
  2. Hypogammaglobulinemia (IgG levels \<5 g/L) as confirmed by the Central Laboratory.
  3. ≥18 years of age.
  4. Voluntarily given, fully informed written and signed consent obtained before any study-related procedures are conducted.

Exclusion criteria

Exclusion Criteria:

  1. IgG treatment within 3 months prior to Screening.
  2. Antibiotic prophylaxis and/or treatment within 7 days prior to Baseline (with the exception of trimethoprim-sulfamethoxazole [TMP/SMX], diaminodiphenyl sulfone [dapsone] and pentamidine inhalation).
  3. Current major infection or >1 major infection in the previous 6 months before Baseline.
  4. History of anaphylaxis or severe systemic response to immunoglobulin, blood or plasma-derived products or any Panzyga component.
  5. History of a non-CLL or other medical condition with life-expectancy of less than two years.
  6. Severe liver disease, with signs of ascites and/or hepatic encephalopathy.
  7. Severe kidney disease (as defined by estimated [eGFR] \<30 mL/min/1.73 m2).
  8. Body weight >140 kg.
  9. (ECOG) performance score of >2 (Appendix 1).
  10. Female patients of unwilling to use a protocol-required method of (as per protocol section 7.3.9 b) from the Screening Visit throughout the study treatment period and for 30 days following the last dose of study drug.
  11. (HIV) infection at Screening (defined for the study as positive HIV antibody test).
  12. Patients found to be chronic carriers of virus (HBV), defined by positive surface antigen (HBsAg), positive Hepatitis B core antibodies (HBcAb) and/or low HBV titers, who will not receive targeted antiviral therapy while undergoing CLL therapy, and patients with active HBV, defined as high HBV titers.
  13. Uncontrolled infection at Screening (defined for the study as positive hepatitis virus C [HCV] polymerase chain reaction [PCR]).
  14. Pregnant and lactating women.
  15. Subjects with a history of thromboembolic events (TEE) such as deep vein thrombosis, pulmonary embolism, myocardial infarction, ischemic stroke, , peripheral artery disease (Fontaine IV) within 6 months before Baseline.
  16. Planned or ongoing treatment (other than for CLL or ) or other forbidden medication during the entire study duration after study enrollment.
  17. Participation in another interventional clinical trial that is either blinded or involves an (not approved) product within 3 months before Baseline or during the course of the clinical study. Participation in observational clinical trials or open-label trials involving an approved product may be permitted after consultation with the medical monitor.
  18. Known IgA deficiency with antibodies to IgA.
  19. Known blood hyperviscosity, or other hypercoagulable states.
  20. Patients unable or unwilling to understand or comply with the study protocol.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
247 participants (actual)

Study arms

  • Experimental
    Panzyga

    Biological: Panzyga

  • Placebo comparator
    Placebo

    Other: Placebo

Interventions

  • BiologicalPanzyga

    Panzyga is a 10% IVIG produced from a pool of human fresh frozen plasma donations

  • OtherPlacebo

    Placebo

06

What researchers measure

Primary outcomes

  1. Occurrence of Major Infections

    The occurrence of major infections was measured as number of participants with major infections. Major infection for this trial was defined as: * Bacterial and/or viral infections resulting in death * Bacterial and/or viral infections, which are microbiologically documented or clinically documented requiring treatment with anti-infectives; upper respiratory tract infections, bronchitis, lower urinary tract infections, localized skin infections and stomatitis are considered major only if they require treatment with antiinfectives AND hospitalization or hospitalization prolongation. * Fever of unknown origin requiring hospitalization or hospitalization prolongation

    Time frame: From first treatment to the occurrence of a major infection or to the end of study visit. The median study duration of participants completing the study was 366 days. For delayed end of study visits 3 participants stayed in the study for 407 days or more.

Secondary outcomes

  1. Overall Infection Rate

    Overall infection rate was measured as number of all infections per person year. Person years include participants who experienced at least one infection during the study or who completed the study without experiencing any infection.

    Time frame: From first treatment to last study visit, with a median time frame of 365 days. For delayed end of study visits 3 participants stayed in the study for 407 days or more.

  2. Frequency of Prophylaxis With Anti-infectives

    Frequency of prophylaxis was defined as the number of prophylactic anti-infective medications, received per participant. Prophylactic anti-Infective medications included antibacterials and antivirals. They were defined as any medications recorded with the indication 'Infection prophylaxis' and qualifying drug code according to WHO Drug Standardised Drug Grouping 'Anti-infectives'.

    Time frame: From first treatment to last study visit, with a median time frame of 365 days. For delayed end of study visits 3 participants stayed in the study for 407 days or more.

  3. Duration of Prophylaxis With Anti-infectives

    Duration of prophylaxis was defined as the sum of the number of days of the participants received prophylaxis with anti-infectives. Prophylactic anti-Infective medications included antibacterials and antivirals.

    Time frame: From first treatment to last study visit, with a median time frame of 365 days. For delayed end of study visits 3 participants stayed in the study for 407 days or more.

07

Results

Posted Nov 2, 2026

Participant flow

This study was conducted at 57 study centers in 10 countries i.e., in the United States, Russia, Greece, Spain, Hungary, Italy, Czech Republic, Denmark, Poland, and Türkiye. The first participant was enrolled in October 2020 and the last participant completed the study in September 2025.

Participant flow — Overall Study
MilestonePanzygaPlacebo
Started124123
Completed9489
Not completed3034
Withdrew: Withdrawal by subject918
Withdrew: Adverse event1610
Withdrew: Protocol violation44
Withdrew: Lost to follow-up12

Outcome measures

PrimaryOccurrence of Major Infections

The occurrence of major infections was measured as number of participants with major infections. Major infection for this trial was defined as: * Bacterial and/or viral infections resulting in death * Bacterial and/or viral infections, which are microbiologically documented or clinically documented requiring treatment with anti-infectives; upper respiratory tract infections, bronchitis, lower urinary tract infections, localized skin infections and stomatitis are considered major only if they require treatment with antiinfectives AND hospitalization or hospitalization prolongation. * Fever of unknown origin requiring hospitalization or hospitalization prolongation

Time frame:
From first treatment to the occurrence of a major infection or to the end of study visit. The median study duration of participants completing the study was 366 days. For delayed end of study visits 3 participants stayed in the study for 407 days or more.
Reported as:
Count of participants · Participants
Occurrence of Major Infections
ParticipantsPanzygaPlacebo
Occurrence of Major Infections1427
Statistical analysis
  • Panzyga vs Placebo · z-test 1-sided · p = 0.0108 · Mean difference (net): -13.2Missing endpoint data for randomized but untreated or lost-to-follow-up patients were multiply imputed, assuming missing at random, with treatment as a factor. Including imputed data, the proportions were 14.2% and 27.4%, respectively.
SecondaryOverall Infection Rate

Overall infection rate was measured as number of all infections per person year. Person years include participants who experienced at least one infection during the study or who completed the study without experiencing any infection.

Time frame:
From first treatment to last study visit, with a median time frame of 365 days. For delayed end of study visits 3 participants stayed in the study for 407 days or more.
Reported as:
Number · number of infections per person year
Overall Infection Rate
number of infections per person yearPanzygaPlacebo
Overall Infection Rate1.151.65
Statistical analysis
  • Panzyga vs Placebo · Regression, Linear · p = 0.0463 · Mean rate ratio: 0.70Missing endpoint data for randomized but untreated or lost-to-follow-up patients were multiply imputed, assuming missing at random, with treatment as a factor.
SecondaryFrequency of Prophylaxis With Anti-infectives

Frequency of prophylaxis was defined as the number of prophylactic anti-infective medications, received per participant. Prophylactic anti-Infective medications included antibacterials and antivirals. They were defined as any medications recorded with the indication 'Infection prophylaxis' and qualifying drug code according to WHO Drug Standardised Drug Grouping 'Anti-infectives'.

Time frame:
From first treatment to last study visit, with a median time frame of 365 days. For delayed end of study visits 3 participants stayed in the study for 407 days or more.
Reported as:
Mean · number of medication per participant
Frequency of Prophylaxis With Anti-infectives
number of medication per participantPanzygaPlacebo
Frequency of Prophylaxis With Anti-infectives1.9 ± 1.261.9 ± 0.78
SecondaryDuration of Prophylaxis With Anti-infectives

Duration of prophylaxis was defined as the sum of the number of days of the participants received prophylaxis with anti-infectives. Prophylactic anti-Infective medications included antibacterials and antivirals.

Time frame:
From first treatment to last study visit, with a median time frame of 365 days. For delayed end of study visits 3 participants stayed in the study for 407 days or more.
Reported as:
Median · sum of number of days
Duration of Prophylaxis With Anti-infectives
sum of number of daysPanzygaPlacebo
Duration of Prophylaxis With Anti-infectives363.0 (3 to 380)363.0 (1 to 407)

Adverse events

Collected over 52 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Panzyga9/124 (7.3%)34/124 (27.4%)70/124 (56.5%)
Placebo7/123 (5.7%)43/123 (35%)69/123 (56.1%)
Most frequent serious events
Showing 10 of 69
Most frequent serious events
EventPanzygaPlacebo
PneumoniaInfections and infestations4/1249/123
COVID-19 pneumoniaInfections and infestations5/1244/123
COVID-19Infections and infestations3/1242/123
Cardiac arrestCardiac disorders1/1242/123
Lower respiratory tract infectionInfections and infestations1/1242/123
InfectionInfections and infestations2/1240/123
Richter's syndromeNeoplasms benign, malignant and unspecified (incl cysts and polyps)2/1240/123
AnaemiaBlood and lymphatic system disorders0/1241/123
Autoimmune haemolytic anaemiaBlood and lymphatic system disorders0/1241/123
Febrile neutropeniaBlood and lymphatic system disorders1/1241/123
Most frequent other events
Showing 10 of 12
Most frequent other events
EventPanzygaPlacebo
NeutropeniaBlood and lymphatic system disorders15/12423/123
Upper respiratory tract infectionInfections and infestations12/12421/123
COVID-19Infections and infestations17/12419/123
PyrexiaGeneral disorders11/1246/123
HypertensionVascular disorders11/1248/123
DiarrhoeaGastrointestinal disorders10/1247/123
Urinary tract infectionInfections and infestations4/1248/123
AnaemiaBlood and lymphatic system disorders8/1245/123
Infusion related reactionInjury, poisoning and procedural complications8/1242/123
CoughRespiratory, thoracic and mediastinal disorders8/1245/123

Baseline characteristics

Age, Customized
Age, Customized(Participants)PanzygaPlaceboTotal
<=17 years000
between >=18 and <65 years444892
>=65 years8075155
Sex: Female, Male
Sex: Female, Male(Participants)PanzygaPlaceboTotal
Female425193
Male8272154
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PanzygaPlaceboTotal
Hispanic or Latino022
Not Hispanic or Latino123121244
Unknown or Not Reported101
Body Mass Index
Body Mass Index(kg/m^2)PanzygaPlaceboTotal
Mean26.92 ± 4.49226.71 ± 4.64126.81 ± 4.559
08

Study locations

84 sites
  • Octapharma Research Site
    St. Petersburg, Florida 33709, United States
  • Octapharma Research Site
    Columbus, Georgia 31904, United States
  • Octapharma Research Site
    Macon, Georgia 31201, United States
  • Octapharma Research Site
    New Orleans, Louisiana 70112, United States
  • Octapharma Research Site
    Baltimore, Maryland 21201, United States
  • Octapharma Research Site
    Baltimore, Maryland 21205, United States
  • Octapharma Research Site
    Detroit, Michigan 48093, United States
  • Octapharma Research Site
    Rochester, Minnesota 55902, United States
  • Octapharma Research Site
    Buffalo, New York 14260, United States
  • Octapharma Research Site
    New York, New York 10032, United States
  • Octapharma Research Site
    New York, New York 10065, United States
  • Octapharma Research Site
    Shirley, New York 11967, United States
  • Octapharma Research Site
    Durham, North Carolina 27710, United States
  • Octapharma Research Site
    Charleston, South Carolina 29414, United States
  • Octapharma Research Site
    Houston, Texas 77090, United States
  • Octapharma Research Site
    Brno, 625 00, Czechia
  • Octapharma Research Site
    Hradec Králové, 500 05, Czechia
  • Octapharma Research Site
    Ostrava, 70852, Czechia
  • Octapharma Research Site
    Aalborg, 9000, Denmark
  • Octapharma Research Site
    Herning, 7400, Denmark
  • Octapharma Research Site
    Roskilde, 4000, Denmark
  • Octapharma Research Site
    Dortmund, 44263, Germany
  • Octapharma Research Site
    Frankfurt, 15236, Germany
  • Octapharma Research Site
    Kiel, 24105, Germany
  • Octapharma Research Site
    Marburg, 35037, Germany
  • Octapharma Research Site
    Athens, 10676, Greece
  • Octapharma Research Site
    Athens, 11526, Greece
  • Octapharma Research Site
    Athens, 12462, Greece
  • Octapharma Research Site
    Ioannina, 45500, Greece
  • Octapharma Research Site
    Pátrai, 26500, Greece
  • Octapharma Research Site
    Thessaloniki, 57010, Greece
  • Octapharma Research Site
    Budapest, 1088, Hungary
  • Octapharma Research Site
    Debrecen, 4032, Hungary
  • Octapharma Research Site
    Győr, 9023, Hungary
  • Octapharma Research Site
    Kaposvár, 7400, Hungary
  • Octapharma Research Site
    Nyíregyháza, 4400, Hungary
  • Octapharma Research Site
    Haifa, 3109601, Israel
  • Octapharma Research Site
    Haifa, 34362, Israel
  • Octapharma Research Site
    Petah Tikva, 49100, Israel
  • Octapharma Research Site
    Castelfranco Veneto, 31033, Italy
  • Octapharma Research Site
    Milan, 20132, Italy
  • Octapharma Research Site
    Milan, 20162, Italy
  • Octapharma Research Site
    Modena, 41124, Italy
  • Octapharma Research Site
    Orbassano, 10043, Italy
  • Octapharma Research Site
    Padova, 35129, Italy
  • Octapharma Research Site
    Pescara, 65124, Italy
  • Octapharma Research Site
    Reggio Calabria, 89133, Italy
  • Octapharma Research Site
    Rome, 00161, Italy
  • Octapharma Research Site
    Torino, 10126, Italy
  • Octapharma Research Site
    Bialystok, 15-732, Poland
  • Octapharma Research Site
    Bydgoszcz, 85-065, Poland
  • Octapharma Research Site
    Gdansk, 80-214, Poland
  • Octapharma Research Site
    Gdansk, 80-219, Poland
  • Octapharma Research Site
    Gdynia, 81-519, Poland
  • Octapharma Research Site
    Katowice, 40-519, Poland
  • Octapharma Research Site
    Legnica, 59-220, Poland
  • Octapharma Research Site
    Lodz, 93-513, Poland
  • Octapharma Research Site
    Torun, 87-100, Poland
  • Octapharma Research Site
    Warsaw, 02-776, Poland
  • Octapharma Research Site
    Wroclaw, 50-367, Poland
  • Octapharma Research Site
    Barnaul, 656024, Russia
  • Octapharma Research Site
    Kemerovo, 650066, Russia
  • Octapharma Research Site
    Moscow, 115478, Russia
  • Octapharma Research Site
    Moscow, 125284, Russia
  • Octapharma Research Site
    Nizhny Novgorod, 603126, Russia
  • Octapharma Research Site
    Novosibirsk, 630051, Russia
  • Octapharma Research Site
    Petrozavodsk, 185019, Russia
  • Octapharma Research Site
    Rostov-on-Don, 344037, Russia
  • Octapharma Research Site
    Saint Petersburg, 191024, Russia
  • Octapharma Research Site
    Samara, 443079, Russia
  • Octapharma Research Site
    Tomsk, 634063, Russia
  • Octapharma Research Site
    Tula, 300053, Russia
  • Octapharma Research Site
    Ufa, 450008, Russia
  • Octapharma Research Site
    Yekaterinburg, 620102, Russia
  • Octapharma Research Site
    Madrid, 28034, Spain
  • Octapharma Research Site
    Madrid, 28040, Spain
  • Octapharma Research Site
    Madrid, 28046, Spain
  • Octapharma Research Site
    Oviedo, 33011, Spain
  • Octapharma Research Site
    Santander, 39008, Spain
  • Octapharma Research Site
    Ankara, 65900, Turkey (Türkiye)
  • Octapharma Research Site
    Antalya, 7050, Turkey (Türkiye)
  • Octapharma Research Site
    Istanbul, 34093, Turkey (Türkiye)
  • Octapharma Research Site
    Izmir, 35100, Turkey (Türkiye)
  • Octapharma Research Site
    Kayseri, 38039, Turkey (Türkiye)
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2020 to primary completion in Sep 2025, 59 months.

Results were first posted in Nov 2026, 1 year 1 month after primary completion.

Of 57 industry-sponsored phase 3 interventional studies under Leukemia, Lymphocytic, Chronic, B-Cell, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 73. This study's 59 months is above that.

Counting every sponsor, half of 83 studies reached it within 59 months; a quarter within 43 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 4, 2020
First posted
Aug 6, 2020
StartActual
Oct 5, 2020
Primary completionActual
Sep 19, 2025
CompletionActual
Sep 19, 2025
Results first posted
Nov 2, 2026
Last update
Nov 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Nov 2, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedOccurrence of major infectionsMajor InfectionsTime frame: 52 weeks → From first treatment to the occurrence of a major infection or to the end of study visit. The median study duration of participants completing the study was 366 days. For delayed end of study visits 3 participants stayed in the study for 407 days or more.
Nov 2, 2026
Documents
Secondary outcomes
3 edited
What changed in the outcomes
  • EditedOverall infection rateInfection RateTime frame: 52 weeks → From first treatment to last study visit, with a median time frame of 365 days. For delayed end of study visits 3 participants stayed in the study for 407 days or more.
  • EditedFrequency of prophylaxis with antiProphylaxis With Anti-infectivesTime frame: 52 weeks → From first treatment to last study visit, with a median time frame of 365 days. For delayed end of study visits 3 participants stayed in the study for 407 days or more.
  • EditedDuration of prophylaxis with antiProphylaxis With Anti-infectivesTime frame: 52 weeks → From first treatment to last study visit, with a median time frame of 365 days. For delayed end of study visits 3 participants stayed in the study for 407 days or more.
Nov 2, 2026
Show all 1 update
  1. Nov 2, 2026
    Results posted
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedOccurrence of major infectionsMajor InfectionsTime frame: 52 weeks → From first treatment to the occurrence of a major infection or to the end of study visit. The median study duration of participants completing the study was 366 days. For delayed end of study visits 3 participants stayed in the study for 407 days or more.
    Secondary outcomes 3 edited
    What changed in the outcomes
    • EditedOverall infection rateInfection RateTime frame: 52 weeks → From first treatment to last study visit, with a median time frame of 365 days. For delayed end of study visits 3 participants stayed in the study for 407 days or more.
    • EditedFrequency of prophylaxis with antiProphylaxis With Anti-infectivesTime frame: 52 weeks → From first treatment to last study visit, with a median time frame of 365 days. For delayed end of study visits 3 participants stayed in the study for 407 days or more.
    • EditedDuration of prophylaxis with antiProphylaxis With Anti-infectivesTime frame: 52 weeks → From first treatment to last study visit, with a median time frame of 365 days. For delayed end of study visits 3 participants stayed in the study for 407 days or more.
    + 4 other changes: identifiers, verification date, site details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT04502030
Lead sponsor
Octapharma
Responsible party
Sponsor
First posted
Aug 6, 2020
Start date
Oct 5, 2020
Primary completion
Sep 19, 2025
Completion
Sep 19, 2025
Results posted
Nov 2, 2026
Last update
Nov 2, 2026

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Panzyga

Start the discussion